Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence

Circulation

Volumn 97, Issue 2, 1998, Pages 211-218

  Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Coronary thrombus; Fibrinolytic theraphy; Myocardial referfusion; Platelets; Thrombolytic theraphy

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LAMIFIBAN; LEFRADAFIBAN; ORBOFIBAN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; WARFARIN; XEMILOFIBAN;

BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL RESEARCH; CLINICAL TRIAL; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031914990     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.2.211     Document Type: Review

References (78)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous strep to kinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.
3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-22.
4. Ryan TJ, Anderson JL, Amman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Teigel BJ, Russell RO, Smith EE, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1996;94:2341-2350.
5. GUSTO Angiographie Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
6. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators. The link between the angiographie substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: the importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923-1928.
7. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
8. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, Califf RM. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I Trial. Circulation. 1995;92:2811-2818.
9. GUSTO-III Investigators. An international, randomized comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
10. The GUSTO II Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator and recomhinant himdin with heparin for acute myocardial infarction. N Engl J Med. 1997;336:1621-1928.
11. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strezelecki M, Puchrowica-Ochocki S, O'Neill WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328:673-679.
12. Ziljstra F, Jan de Boer M, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680-684.
13. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh B. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993;328:685-691.
14. Weaver WD, Simes RJ, Betriu A, et al. Primary coronary angioplasty vs. intravenous thrombolysis for treatment of acute myocardial infarction: a quantitative overview of their comparative effectiveness. JAMA. In press.
15. Horrigan MG, Topol EJ. Direct angioplasty in acute myocardial infarction: state of the art and current controversies. Cardiol Clin. 1995;1.3:321-338.
16. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
17. Simoons ML, Arnold AER, Betriu A, DeBono DP, Col J, Dougherty FC, von Essen R, Lambertz H, Lubsen J, Meier B, Michel PL, Raynaud P, Rutsch W, Sanz GA, Schmidt W, Serruys PW, Thery C, Vebis R, Vahaniam A, Van de Werf F, Willems GM, Wood G, Verstraete M. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous transluminal coronary angioplasty. Lancet. 1988;1:197-203.
18. TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. JAMA. 1988;260:2849-2858.
19. Holmes DR, Topol EJ. Reperfusion momentum: lessons from the randomized trials of immediate coronary angioplasty for acute myocardial infarction. J Allergy Clin Immunol. 1989;14:1572-1578.
20. SWIFT Trial Study Group. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ. 1991;302:555-560.
21. Rapold JH, de Bono D, Arnold AER, Arnout J, DeCock F, Collen D, Verstraete M. for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase: correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation. 1992;85:928-934.
22. Rapold HJ, Brimaudo V, Declerck PJ, Kruithof KO, Bachmann F. Plasma levels of plasminogen activator inhibitor type 1, B-thromboglobulin and fibrinopeptide A before, during and after treatment of acute myocardial infarction with alteplase. Blood. 1991;78:1490-1495.
23. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
24. Thieme T, Wernecke KD, Meyer R, Brandenstein E, Habedank D, Hinz A, Felix SB, Baumann G, Kleber FX. Angioscopic evaluation of atherosclerotic plaques: validation by histomorphologic analysis and association with stable and unstable coronary syndromes. J Allergy Clin Immunol. 1996;28:1-6.
25. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation. 1996;93:1328-1330.
26. Willerson JT, Campbell WB, Winniford MD, Schmitz J, Apprill P, Firth BG, Ashton J, Smitherman T, Bush L, Buja LM. Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms. J Allergy Clin Immunol. 1984;54:1349-1354.
27. Hirsh PD, Hillis CD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981;304:685-691.
28. Willerson JT, Hillis LD, Winniford M, Buja M. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes. J Allergy Clin Immunol. 1986;8:245-250.
29. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Circulation. 1989;80: 198-205.
30. 2 and serotonin after thrombolysis -with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation. 1988;77:678-684.
31. 2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation. 1989;79:911-919.
32. Golino P, Rosolowsky M, Yao SK, McNatt J, DeClerck F, Buja LM, Willerson JT. Endogenous prostaglandin endoperoxides and prosracyclin modulate the thrombolytic activity of tissue plasminogen activator. J Clin Invest. 1990;86:1095-1102.
33. Golion P, Willerson JT. Is thrombolysis alone the best therapy for acute myocardial infarction? Texas Heart Inst J. 1991;18:50-61.
34. Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
35. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
36. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Columbo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-A, for the BENESTENT Study Group. A comparison of balloon-expandable-stent Implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
37. Fischman DL, Leon MB, Bairn DS, Schantz RA, Savage MP, Penn I, Detre K, Veltri I, Ricci D, Nobuyoshi M, Cleman M, Meuser R, Almond D, Teirstein PS, Fish RD, Columbo A, Brinker J, Moses J, Shaknovich A, Hirshfield J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of stent placement and balloon angioplasty in the treatment of coronary artery disease, N Engl Med. 1994;331:496-501.
38. Topol EJ. Caveats about elective coronary stenring. N Engl J Med. 1994;331:539-541.
39. Topol EJ. The stentor and the sea change. Am J Cardiol. 1995;76:307- 308.
40. Schomig A, Neumann F-J, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
41. Bertrand M, Legrand V, BolandJ, Fleck E, Bonnier J, Emmanuelson H. Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L. Full anticoagulation versus ticlopidine plus aspirin after stent implantation: a randomized multicemer European study: the FANTASTIC trial. Circulation. 1996;94(suppl I):I-685. Abstract.
42. Leon MB, Bairn DS, Gordon P, Giambartolomei A, Williams DO, Diver DO, Senerchia C, Fitzpatrick M, Popma JJ, Kuntz RE. Clinical and angiographie results from the STent Anticoagularion Regimen Study (STARS). Circulation. 1996;94(suppl I):I-685. Abstract.
43. Mak KH, Belli G, ElHs SG, Molitemo DJ. Subacute stent thrombosis: evolving issues and current concepts. J Allergy Clin Immunol 1996;27:494-503.
44. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
45. EPILOG Invesngators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revasculanzation. N Engl J Med. 1997;336:1689-1696.
46. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol. 1996;78(suppl 3A):35-40.
47. The IMPACT II Investigators. Effects of competitive platelet glycoprotein IIb/IIIa inhibition with Integrilm in reducing complications ot percutaneous coronary intervention. Lancet. 1997;349:1422-1428.
48. Simoons M. Chimeric 7E3 AntiPlatelet in Unstable Angina Refractory to Standard Treatment (CAPTURE). Presented at the European Society- of Cardiology, Birmingham. UK, August 1996.
49. PARAGON Investigators. A randomized trial of potent platelet IIb/IIIa antagonism, heparin or both in patients with unstable angina: the PARAGON Study. Circulation. 1996;94:I-553. Abstract.
50. White H. Platelet Receptor Inhibition for Ischemic Syndrome Management study (PRISM). Presented at the American College of Cardiology, Anaheim, Calif, March 1997.
51. Theroux P. Platelet Receptor Inhibition for Ischémie Syndrome Management Study (PRISM) Plus. Presented at the American College of Cardiology, Anaheim, Calif, March 1997.
52. Platelet IIb/IIIa Underpinning the Receptor for Suppression of Unstable Ischemia Trial (PURSUIT). Presented at the XIX Congress of the European Society of Cardiology, Stockholm, Sweden, August 24-28, 1997.
53. Theroux P, Kouz S, Roy L, Khudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban study. Circulation. 1996;94:899-905.
54. Anciplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
55. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe K, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
56. 3 blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
57. Coller BS. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Artery Dis. 1992;3:1016-1029.
58. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation. 1988;77:670-677.
59. Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GP IIb/IIIa antibody. J Am Coll Cardiol. 1990;7:1728-1735.
60. Shebuski RJ, Stabihto IJ, Sitko GR, Polokoff MH. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation. 1990;82:169-177.
61. Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Kistrin, a polypeptide platelet GP IIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation. 1991;83:1038-1047.
62. 2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation. 1990;81:617-627.
63. Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ. Prevention of reocclusion following tissue-type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis. Pharmacology. 1991;42:340-348.
64. Modi NB, Reynolds T, Baughman SA, Thomas DA, Paasch BD, Smith SY. Pharmacokinetics and phannacodynamics of TP-9201, a GP IIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. J Cardiovasc Pharmacol. 1996;27:105-112
65. Nicolmi FA, Lee P, Rios G. Kottke-Marchant K. Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct antithrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 1994;89: 1802-1809.
66. Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadvary P. Effects of hepann. aspirin and a synthetic platelet glycoprotein IIb/IIIa receptor antagonist (Ro 43-5054) on coronary artery repertusion and reocclusion alter thrombolysis with tissue-type plasminogen activator in the dog. J Pharmacol Exp Ther. 1993;264:501-508.
67. Rapold HJ, Gold HK, Wu Z, Napier M, Bunting S, Collen D. Effects of G4120, a Arg-Gly-Asp containing synthetic platelet glycoprotein IIb/IIIa receptor antagonist, on arterial and venous thrombolysis with recombinant tissue-type plasminogen activator in dogs. Fibrinilysis. 1993;7:248-256.
68. Yasuda T, Gold HK, Kohmura C, Guerrero L, Yaoita H, Fallon JT, Bunting S, Collen D. Intravenous and endobronchial administration of G4120, 3 cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptorblocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arterioscler Thromb. 1993;13:738-747.
69. Kanu S, Kawasaki T, Hisamichi N, Sakai Y, Taniuchi Y, Inagaki O, Yano S, Suzuki K, Terazaki C, Masuho Y, Satoh N, Takenaka T, Yanagi K, Ohshima N. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GP IIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996;75:679-684.
70. Kohmura C, Gold HK, Yasuda T, Holdt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D. A chimeric murine/human antibody Fab fragment directed against the platelet GP IIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator m baboons. Anenoscler Thromb. 1993;13:1837-1842.
71. Kaida T, Matsuno H, Niwa M, Kozawa O, Miyata H, Uematsu T. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery. Thromb Haemost. 1997;77:562-567.
72. Kleiman NS, Ohman EM, Califf RM, George BS, Kereliakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Allergy Clin Immunol. 1993;22:381-389.
73. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen SD, Spriggs D, Miller M, Kereiakes D, Yakulov S. Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial intarctaon. Circulation. 1997;95:846-854.
74. Molitemo DJ, Harrington RA, Krucoff MW, Armstrong PW, Van de Werf F, Kristinsson A. Hul W, Paraschos A, Bhapkar M, Rames A, Topol EJ, for the PARADIGM Investigators. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: the PARADIGM Trial. Circulation. 1996;94(suppl I):I-553. Abstract.
75. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, for the IMPACT Investigators. Multicenter, randomized, double-blind placebo-controlled trial of the platelet imegrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention. Circulation. 1995;91:2151-2157.
76. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, Leinbach RC. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation. 1997; 95:1755-1759.
77. Lefkovits J, Ivanhoe RJ, Califf RM, Bergekon BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ, for the EPIC Invesrigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody improves acute and 6-month outcomes following PTCA for acute myocardial infarction: insights from the EPIC Trial. Am J Cardiol. 1996;77:1045-1051.
78. Topol EJ. RAPPORT: outcomes in patients with acute myocardial infarction with abciximab and primary PTCA. Presented at the XIX Congress of the European Society of Cardiology, Stockholm, Sweden.